Candriam S.C.A. Keros Therapeutics, Inc. Transaction History

Candriam S.C.A.

$15.4 Billion
Q1 2024

A detailed history of Candriam S.C.A. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 651,999 shares of KROS stock, worth $29.8 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

651,999

Previous 819,062 20.4%

Holding current value

$29.8 Million

Previous $32.6 Million 32.54%

% of portfolio

0.28%

Previous 0.23%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$41.26 - $70.48 $6.89 Million - $11.8 Million	-167,063 Reduced 20.4%	651,999 $43.2 Million
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $2.12 Million - $3.2 Million	78,001 Added 10.53%	819,062 $32.6 Million
Q3 2023 Nov 13, 2023	BUY	$31.57 - $43.02 $631,400 - $860,400	20,000 Added 2.77%	741,061 $23.6 Million
Q2 2023 Aug 08, 2023	SELL	$37.26 - $51.01 $894,090 - $1.22 Million	-23,996 Reduced 3.22%	721,061 $29 Million
Q1 2023 May 12, 2023	BUY	$41.44 - $59.32 $4.94 Million - $7.07 Million	119,143 Added 19.04%	745,057 $31.8 Million

Q4 2022 Feb 13, 2023	BUY	$39.45 - $51.77 $10.4 Million - $13.7 Million	264,125 Added 73.01%	625,914 $30.1 Million
Q2 2022 Aug 03, 2022	SELL	$26.03 - $67.04 $1.53 Million - $3.95 Million	-58,881 Reduced 14.0%	361,789 $10 Million
Q1 2022 May 13, 2022	BUY	$42.12 - $59.36 $7.57 Million - $10.7 Million	179,724 Added 74.59%	420,670 $22.9 Million
Q3 2021 Nov 09, 2021	BUY	$29.27 - $43.71 $4.08 Million - $6.1 Million	139,537 Added 137.6%	240,946 $9.53 Million
Q2 2021 Jul 20, 2021	BUY	$42.4 - $70.11 $4.3 Million - $7.11 Million	101,409 New	101,409 $4.31 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account